Compare PARK & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PARK | ENTX |
|---|---|---|
| Founded | 1972 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Misc Health and Biotechnology Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.6M | 74.7M |
| IPO Year | N/A | 2015 |
| Metric | PARK | ENTX |
|---|---|---|
| Price | $17.17 | $1.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 26.9K | ★ 104.1K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.18 |
| Revenue | N/A | ★ $181,000.00 |
| Revenue This Year | $7.06 | N/A |
| Revenue Next Year | $6.17 | N/A |
| P/E Ratio | $6.47 | ★ $6.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.29 | $1.00 |
| 52 Week High | $21.60 | $3.22 |
| Indicator | PARK | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.18 | 36.00 |
| Support Level | $14.41 | $1.09 |
| Resistance Level | $21.33 | $1.61 |
| Average True Range (ATR) | 1.26 | 0.17 |
| MACD | -0.29 | -0.02 |
| Stochastic Oscillator | 29.87 | 18.63 |
Park Dental Partners Inc is a dental resource organization (DRO) operating through its subsidiary. It Provides comprehensive business support services including clinical team members, administrative personnel, facilities and equipment to its affiliated general and multi-specialty dental practices throughout Minnesota and Wisconsin. Its network of affiliated dental practices provides both general and specialty dental services, including oral surgery, periodontics, pediatric dentistry, prosthodontics, endodontics, and orthodontics, under long-term agreements with initial terms of 30-years, with automatic 5-year renewals.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.